NCT02490891 (RGDLymphome) is a Phase 2 clinical trial of RGD K5 PET scan in Lymphoma, sponsored by Centre Henri Becquerel.

Who is sponsoring NCT02490891?

NCT02490891 is sponsored by Centre Henri Becquerel.

What drugs are being tested in NCT02490891?

Interventions in NCT02490891: RGD K5 PET scan.

Is NCT02490891 still recruiting?

NCT02490891 is currently completed. Last updated 2 January 2026.

Last reviewed 2026-01-02 · How we verify

NCT02490891: RGDLymphome

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of the Angiogenesis by PET/CT in Patients With Lymphoma

Completed Phase 2 Last updated 2 January 2026

What this trial tests

Phase 2 trial testing RGD K5 PET scan in Lymphoma in 21 participants. Completed in 16 October 2020.

Timeline

13 November 2015

Primary endpoint
14 December 2018

16 October 2020

Quick facts

Lead sponsor	Centre Henri Becquerel
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Primary purpose	other
Enrollment	21
Start date	13 November 2015
Primary completion	14 December 2018
Estimated completion	16 October 2020
Sites	1 location across France

Drugs / interventions tested

RGD K5 PET scan

Conditions studied

Lymphoma — all drugs for Lymphoma →

Sponsor

Centre Henri Becquerel — full company profile →

Who can join

18 and older, any sex, with Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to measure tumoral angiogenesis modifications by RGD-K5 PET/CT before and after 2 cycles of chemotherapy in patients with lymphoma and a large tumoral mass

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin-RGD interactions.
Javid H, Oryani MA, Rezagholinejad N, Esparham A, et al · · 2024 · cited 137× · PMID 38349028 · DOI 10.1002/cam4.6800
Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?
Fu C, Yu L, Miao Y, Liu X, et al · · 2023 · cited 121× · PMID 36873165 · DOI 10.1016/j.apsb.2022.07.020
Peptide-Drug Conjugates: A New Hope for Cancer Management.
Chavda VP, Solanki HK, Davidson M, Apostolopoulos V, et al · · 2022 · cited 59× · PMID 36364057 · DOI 10.3390/molecules27217232
Skin Cancer Pathobiology at a Glance: A Focus on Imaging Techniques and Their Potential for Improved Diagnosis and Surveillance in Clinical Cohorts.
Dobre EG, Surcel M, Constantin C, Ilie MA, et al · · 2023 · cited 22× · PMID 36674595 · DOI 10.3390/ijms24021079
Angiogenesis imaging study using interim [<sup>18</sup>F] RGD-K5 PET/CT in patients with lymphoma undergoing chemotherapy: preliminary evidence.
Tonnelet D, Bohn MDP, Becker S, Decazes P, et al · · 2021 · cited 5× · PMID 33846870 · DOI 10.1186/s13550-021-00776-9

Verify or expand the search:

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting

Other Centre Henri Becquerel trials

Trials by the same sponsor.

NCT07499765 — Benefits of Formalized Care Support Program Following Acute Leukemia Diagnosis · NA · not yet recruiting
NCT07259915 — Multimodal Prediction of Response to Chemoradiotherapy for Squamous Cell Carcinoma of the Head and Neck · NA · not yet recruiting
NCT07285564 — Performance of 18F-FDG Micro-PET-CT in the Assessment of Surgical Margins in Head and Neck Cancer · NA · recruiting
NCT07190755 — Impact of Patient-Reported Outcomes for Symptom Monitoring in Patients Followed for Head and Neck Squamous Cell Carcinom · NA · recruiting
NCT07029100 — Feasibility of ORGAnoids in Routine Clinical Practice for Molecular Analysis of the GLIOvascular Niche in Patients With · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02490891 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Henri Becquerel
Last refreshed: 2 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02490891.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing